Latest & greatest articles for rheumatoid arthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for rheumatoid arthritis

41. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease

Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease 29764964 2018 05 16 0315-162X 2018 May 15 The Journal of rheumatology J. Rheumatol. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. jrheum.170926 10.3899/jrheum.170926 To evaluate the cardiovascular safety of abatacept (ABA) versus tumor necrosis (...) factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients with and without underlying cardiovascular disease (CVD). We identified RA patients with and without baseline CVD who initiated ABA or TNFi by using data from 2 large US insurance claims databases: Medicare (2008-2013) and Truven MarketScan (2006-2015). After stratifying by baseline CVD, ABA initiators were 1:1 propensity score (PS) matched to TNFi initiators to control for > 60 baseline covariates. Cox proportional hazards regression

EvidenceUpdates2018

42. Rheumatoid arthritis in adults: management

Rheumatoid arthritis in adults: management Rheumatoid arthritis in adults: Rheumatoid arthritis in adults: management management NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng100 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Rheumatoid arthritis in adults: management (NG100) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 31Contents Contents Overview 5 Who is it for? 5

National Institute for Health and Clinical Excellence - Clinical Guidelines2018

43. Baricitinib (Olumiant) - To treat moderately to severely active rheumatoid arthritis

Baricitinib (Olumiant) - To treat moderately to severely active rheumatoid arthritis Drug Approval Package: Olumiant (baricitinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Olumiant (baricitinib) Company: Eli Lilly and Company Application Number: 207924 Approval Date: 05/31/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

FDA - Drug Approval Package2018

44. Use of the Orem self-care model on pain relief in women with rheumatoid arthritis: a randomized trial

Use of the Orem self-care model on pain relief in women with rheumatoid arthritis: a randomized trial 30034655 2018 11 14 2008-5842 10 6 2018 Jun Electronic physician Electron Physician Use of the Orem self-care model on pain relief in women with rheumatoid arthritis: a randomized trial. 6884-6891 10.19082/6884 Self-care is an important tool in controlling pain in patients with rheumatoid arthritis. The aim of this study was to determine the use of the Orem self-care model on pain (...) relief in patients with rheumatoid arthritis. This was a clinical trial performed on 60 patients with rheumatoid arthritis who referred to a rheumatology clinic in Karaj during 2013-2015 (30 patients in the control group and 30 patients in the intervention group), convenience sampling was done and subjects were divided into two groups randomly. Data collecting tools were a demographic questionnaire which consisted of 19 questions and the Numeric Pain Rating Scale. The data result was analyzed by SPSS version 19

Electronic physician2018 Full Text: Link to full Text with Trip Pro

45. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. BACKGROUND: Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. We did this study to further assess the safety and efficacy of upadacitinib in patients (...) with an inadequate response to biologic disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: We did this double-blind, randomised controlled phase 3 trial at 153 sites in 26 countries. Patients were aged 18 years or older, had active rheumatoid arthritis and previous inadequate response or intolerance to bDMARDs, and were receiving concomitant background conventional synthetic DMARDS (csDMARDs). We randomly assigned patients (2:2:1:1) by interactive response technology to receive once-daily oral extended

Lancet2018

46. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. BACKGROUND: Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess the efficacy of upadacitinib in patients with inadequate response (...) to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). METHODS: This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide. Using

Lancet2018

47. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} This 3-arm trial in rheumatoid arthritis stopped early because of contractual issues and commissioning challenges, but 122 randomised participants were followed up, generating evidence for future meta-analyses. {{author}} {{($index , , , , , , , , , & . Sarah Brown 1 , Colin C Everett 1 , Kamran Naraghi 2 , Claire

NIHR HTA programme2018

48. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) Institute ND Not done NS No sample NSAID Nonsteroidal anti-inflammatory drug OBS Observed data PAAP Patient’s Assessment of Arthritis Pain PD Pharmacodynamic(s) PE Physical examination PGA Patient’s Global Assessment of Arthritis PGAA Physician’s Global Assessment of Arthritis PIPD Potentially important protocol deviation PMDA Pharmaceuticals and Medical Devices Agency PK Pharmacokinetic(s) PP Per-Protocol PT Preferred term QC Quality control RA Rheumatoid arthritis RNA Ribonucleic acid SAE Serious

European Medicines Agency - EPARs2018

49. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors

Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors 29760159 2018 05 16 1468-2060 2018 May 14 Annals of the rheumatic diseases Ann. Rheum. Dis. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. annrheumdis-2018-213035 10.1136/annrheumdis-2018-213035 To identify and validate (...) clinical baseline predictors associated with inadequate response (IR) to methotrexate (MTX) therapy in newly diagnosed patients with rheumatoid arthritis (RA). In U-Act-Early, 108 disease-modifying antirheumatic drug (DMARD)-naive patients with RA were randomised to initiate MTX therapy and treated to target until sustained remission (disease activity score assessing 28 joints (DAS28) <2.6 with four or less swollen joints for ≥24 weeks) was achieved. If no remission, hydroxychloroquine was added

EvidenceUpdates2018

50. Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis

Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis 29872356 2018 11 14 1179-156X 10 2018 Open access rheumatology : research and reviews Open Access Rheumatol Serum heat-shock protein-65 antibody levels are elevated but not associated with disease activity in patients with rheumatoid arthritis and ankylosing spondylitis. 55-60 10.2147/OARRR.S162512 Heat-shock proteins (HSPs) have (...) gained increased interest for their role in autoimmune disorders. These proteins are targeted by the immune system in various autoimmune diseases. The aim of this study was to assess the serum heat-shock protein-65 antibody (anti-HSP65) levels and their clinical significance in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). A total of 30 patients with RA, 30 patients with AS, and 30 healthy controls were enrolled in this study. All patients were assessed using routine

Open access rheumatology : research and reviews2018 Full Text: Link to full Text with Trip Pro

51. What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis

What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again (...) . >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Limited evidence suggests ultrasound monitoring of synovitis could provide an effective approach to selecting rheumatoid arthritis patients for biologic treatment tapering or escalation-avoidance. {{author

NIHR HTA programme2018

52. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis 29592917 2018 05 11 1468-2060 77 6 2018 Jun Annals of the rheumatic diseases Ann. Rheum. Dis. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. 905-910 10.1136/annrheumdis-2017-212825 To compare (...) the incidence of serious infection (SI) across biologic drugs used to treat rheumatoid arthritis (RA) using data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). The BSRBR-RA is a prospective observational cohort study. This analysis included patients with RA starting a new biologic. The primary outcome was SI defined as an infectious event requiring admission to hospital, intravenous antibiotics or resulting in death. Event rates were calculated and compared

EvidenceUpdates2018

53. The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts

The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts 29590474 2018 03 28 1462-0332 2018 Mar 26 Rheumatology (Oxford, England) Rheumatology (Oxford) The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early (...) Rheumatoid Arthritis Network UK prospective cohorts. 10.1093/rheumatology/key066 To examine associations between BMI and disease activity, functional ability and quality of life in RA. Data from two consecutive, similarly designed UK multicentre RA inception cohorts were used: the Early RA Study (ERAS) and the Early RA Network (ERAN). Recruitment figures/median follow-up for the ERAS and ERAN were 1465/10 years (maximum 25 years), and 1236/6 years (maximum 10 years), respectively. Standard demographic

EvidenceUpdates2018

54. High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis

High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis 29554376 2018 03 19 1462-0332 2018 Mar 14 Rheumatology (Oxford, England) Rheumatology (Oxford) High-sensitivity cardiac troponin I is a biomarker for occult coronary plaque burden and cardiovascular events in patients with rheumatoid arthritis. 10.1093/rheumatology/key057 Patients with RA display greater occult coronary atherosclerosis burden

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

55. Glucocorticoids Are Associated with An Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis

Glucocorticoids Are Associated with An Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis 29545455 2018 05 02 0315-162X 45 5 2018 May The Journal of rheumatology J. Rheumatol. Glucocorticoids Are Associated with an Increased Risk for Vertebral Fracture in Patients with Rheumatoid Arthritis. 612-620 10.3899/jrheum.170054 To identify the effects of glucocorticoids (GC) on various types of fractures in patients with rheumatoid arthritis (RA). We used the Korean National (...) of Rheumatology, Hanyang University Hospital for Rheumatic Diseases; Y.K. Sung, MD, PhD, MPH, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases. sungyk@hanyang.ac.kr. eng Journal Article 2018 03 15 Canada J Rheumatol 7501984 0315-162X ADMINISTRATIVE CLAIMS FRACTURE GLUCOCORTICOIDS RHEUMATOID ARTHRITIS 2017 11 07 2018 3 17 6 0 2018 3 17 6 0 2018 3 17 6 0 ppublish 29545455 jrheum.170054 10.3899/jrheum.170054

EvidenceUpdates2018

56. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. Rheumatoid arthritis is a systemic autoimmune disease characterized by excess morbidity and mortality from cardiovascular disease. Mechanisms linking rheumatoid arthritis and cardiovascular disease include shared inflammatory mediators, post-translational modifications of peptides/proteins and subsequent immune responses, alterations in the composition and function of lipoproteins, increased oxidative stress (...) , and endothelial dysfunction. Despite a growing understanding of these mechanisms and their complex interplay with conventional cardiovascular risk factors, optimal approaches of risk stratification, prevention, and treatment in the context of rheumatoid arthritis remain unknown. A multifaceted approach to reduce the burden posed by cardiovascular disease requires optimal management of traditional risk factors in addition to those intrinsic to rheumatoid arthritis such as increased disease activity. Treatments

BMJ2018

57. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis 29680881 2018 11 14 2198-6576 5 1 2018 Jun Rheumatology and therapy Rheumatol Ther Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. 43-55 10.1007/s40744-018-0110-x This article (...) evaluates the efficacy and safety of baricitinib 4 mg versus placebo in United States including Puerto Rico (US) and rest of the world (ROW) subpopulations using data pooled from RA-BEAM and RA-BUILD, which enrolled patients with moderate-to-severe adult-onset rheumatoid arthritis (RA). In RA-BEAM, patients with an inadequate response (IR) to methotrexate, at least one X-ray erosion, and high sensitivity C-reactive protein (hsCRP) ≥ 6 mg/L were randomized to placebo or orally administered baricitinib 4

Rheumatology and therapy2018 Full Text: Link to full Text with Trip Pro

58. Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate

Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate NIHR DC | Signal - Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Dissemination Centre Discover Portal NIHR DC Discover Stopping biological drugs for rheumatoid arthritis can lead to twice the relapse rate Published on 24 January 2018 It seems safer to reduce the dose of biological drugs, rather than to stop them if people with rheumatoid arthritis and their doctors want (...) to avoid relapse. Stopping these powerful drugs caused the disease to recur in 58% of people compared with 29% who continued them. Reducing the dose also led to more relapses for people in remission, but did not cause those with low-grade disease activity to worsen. Rheumatoid arthritis is a chronic disease which causes pain, swelling and stiffness in the small joints of the hands and feet. It can cause more widespread inflammation. The disease has episodes of improvement and deterioration so judging

NIHR Dissemination Centre2018

59. Existing drugs for rheumatoid arthritis may also improve associated fatigue

Existing drugs for rheumatoid arthritis may also improve associated fatigue NIHR DC | Signal - Existing drugs for rheumatoid arthritis may also improve associated fatigue Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Existing drugs for rheumatoid arthritis may also improve associated fatigue Published on 23 August 2016 Biological treatments for moderate to severe rheumatoid arthritis appear to reduce fatigue as well as other symptoms. Although existing studies looking (...) to moderate reduction in fatigue, which may be an important consideration for patients and prescribers. Why was this study needed? Rheumatoid arthritis affects around 400,000 people in the UK. It is an autoimmune disease in which the person’s own immune system attacks their body, in this case mainly the joints, causing inflammation, swelling, stiffness, pain and irreversible joint damage. There is no cure for rheumatoid arthritis. Treatments such as anti-inflammatory painkillers aim to relieve symptoms

NIHR Dissemination Centre2018

60. Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis

Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis 30071930 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. 160-164 10.5152/eurjrheum.2018.17148 Adverse changes in body composition, specifically decreased muscle mass (MM (...) ) and increased fat mass, characterize rheumatoid arthritis (RA). These changes, termed rheumatoid cachexia (RC), are important contributors to the disability and elevated co-morbidity risk of RA. Recently, we observed substantial muscle loss (~2 kg) in a patient with RA following a single intramuscular (IM) corticosteroid (CS) injection to treat a disease flare. The aim of the current study is to determine whether this apparent iatrogenic effect of IM CS is typical, i.e., does this routine, recommended

European journal of rheumatology2018 Full Text: Link to full Text with Trip Pro